Pharmos Corporation
to Present at the
Harris
Nesbitt Gerard Focus on Healthcare Conference
Iselin
NJ, December 10, 2003 – Pharmos Corporation
(Nasdaq: PARS) announced today Dr. Haim Aviv, Chairman
& CEO, will present to institutional investors and
analysts attending the Harris Nesbitt Gerard Focus on
Healthcare Conference at the Waldorf-Astoria in New York
City on Thursday, December 11, 2003, at 10:45 a.m. Eastern
Time. Pharmos’ presentation will concentrate on
dexanabinol, the Company’s lead compound under development,
currently being tested clinically for traumatic brain
injury (Phase III trial) and mild cognitive impairment
in cardiac surgery patients (Phase II). The presentation
will also outline other areas of therapeutic potential
held within the Company’s rich neurological pipeline.
A simultaneous webcast of Pharmos’
presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=PARS&item_id=823511.
Pharmos recently announced that it is in
the process of offering shares of its common stock to
the public, subject to market and other conditions. The
offering is being made from a shelf registration statement
filed by Pharmos on November 18, 2003, as amended, that
was declared effective by the Securities and Exchange
Commission on December 2, 2003. C.E. Unterberg, Towbin
and Harris Nesbitt Gerard are acting as underwriters for
the offering.
This press release does not constitute an
offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities
in any state or foreign jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such
state or foreign jurisdiction. The offering of common
stock may be made only be means of a prospectus, a copy
of which is available from C.E. Unterberg, Towbin, 350
Madison Avenue, New York, New York 10017 or Harris Nesbitt
Gerard, 360 Madison Avenue, New York, New York 10017.
Pharmos discovers, develops, and commercializes
novel therapeutics to treat a range of indications, in
particular neurological and inflammation-based disorders.
The Company's first neuroprotective product is dexanabinol,
a tricyclic dextrocannabinoid, currently undergoing clinical
testing as a treatment for TBI and as a preventive agent
against post-surgical cognitive impairment. Other dextrocannabinoid
compounds and selective CB2 receptor agonist compounds
from Pharmos' proprietary synthetic cannabinoid library
are being studied in pre-clinical programs targeting a
variety of other disorders.
Statements made in this press
release related to the business outlook and future financial
performance of the Company, to the prospective market
penetration of its drug products, to the development and
commercialization of the Company’s pipeline products
and to the Company’s expectations in connection
with any future event, condition, performance or other
matter, are forward-looking and are made pursuant to the
safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties
which may cause results to differ materially from those
set forth in these statements. Additional economic, competitive,
governmental, technological, marketing and other factors
identified in Pharmos’ filings with the Securities
and Exchange Commission could affect such results.
Contacts:
Gale T. Smith – U.S.
732.452.9556
Gale.Smith@pharmos-us.com
Irit Kopelov – Israel
08-940-9679
iritk@pharmos.com
back
to News Room
